GM1 ganglioside therapy in acute ischemic stroke

F. Angeleri, O. Scarpino, C. Martinazzo, A. Mauro, M. Magi, G. Pelliccioni, G. Rapex, Roberto Bruno

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalCerebrovascular Diseases
Volume2
Issue number3
DOIs
Publication statusPublished - 1992

Fingerprint

G(M1) Ganglioside
Activities of Daily Living
Stroke
Placebos
Randomized Controlled Trials
Safety
Therapeutics
sialogangliosides

Keywords

  • Cerebral ischemia
  • Excitatory amino acids
  • GM1 ganglioside therapy
  • Monosialoganglioside

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Neurology

Cite this

Angeleri, F., Scarpino, O., Martinazzo, C., Mauro, A., Magi, M., Pelliccioni, G., ... Bruno, R. (1992). GM1 ganglioside therapy in acute ischemic stroke. Cerebrovascular Diseases, 2(3), 163-168. https://doi.org/10.1159/000109009

GM1 ganglioside therapy in acute ischemic stroke. / Angeleri, F.; Scarpino, O.; Martinazzo, C.; Mauro, A.; Magi, M.; Pelliccioni, G.; Rapex, G.; Bruno, Roberto.

In: Cerebrovascular Diseases, Vol. 2, No. 3, 1992, p. 163-168.

Research output: Contribution to journalArticle

Angeleri, F, Scarpino, O, Martinazzo, C, Mauro, A, Magi, M, Pelliccioni, G, Rapex, G & Bruno, R 1992, 'GM1 ganglioside therapy in acute ischemic stroke', Cerebrovascular Diseases, vol. 2, no. 3, pp. 163-168. https://doi.org/10.1159/000109009
Angeleri F, Scarpino O, Martinazzo C, Mauro A, Magi M, Pelliccioni G et al. GM1 ganglioside therapy in acute ischemic stroke. Cerebrovascular Diseases. 1992;2(3):163-168. https://doi.org/10.1159/000109009
Angeleri, F. ; Scarpino, O. ; Martinazzo, C. ; Mauro, A. ; Magi, M. ; Pelliccioni, G. ; Rapex, G. ; Bruno, Roberto. / GM1 ganglioside therapy in acute ischemic stroke. In: Cerebrovascular Diseases. 1992 ; Vol. 2, No. 3. pp. 163-168.
@article{877b337a5dd04974913779b3f9560f8f,
title = "GM1 ganglioside therapy in acute ischemic stroke",
abstract = "A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).",
keywords = "Cerebral ischemia, Excitatory amino acids, GM1 ganglioside therapy, Monosialoganglioside",
author = "F. Angeleri and O. Scarpino and C. Martinazzo and A. Mauro and M. Magi and G. Pelliccioni and G. Rapex and Roberto Bruno",
year = "1992",
doi = "10.1159/000109009",
language = "English",
volume = "2",
pages = "163--168",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - GM1 ganglioside therapy in acute ischemic stroke

AU - Angeleri, F.

AU - Scarpino, O.

AU - Martinazzo, C.

AU - Mauro, A.

AU - Magi, M.

AU - Pelliccioni, G.

AU - Rapex, G.

AU - Bruno, Roberto

PY - 1992

Y1 - 1992

N2 - A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).

AB - A double-blind, randomized, placebo-controlled clinical trial, involving two Italian centers, was carried out to evaluate the efficacy and safety of the mono-sialoganglioside GM1 in acute ischemic stroke. A total of 112 consecutive patients were recruited. The treatment (GM1 or placebo) was intravenously administered for 3 weeks and the follow-up lasted for 6 months. Semiquanti- tative clinical evaluations were performed on admission at the end of treat¬ment (day 21) and at the end of follow-up (day 180), by using the Frithz- Werner Scale for the neurological recovery and the Barthel Index for the activ¬ities of daily living. On day 21, the statistical analysis showed a significant neurological improvement (p <0.01) in the Frithz-Werner Scale in favor of the GM1 group. On day 180, the difference between the two groups was not significant for the Frithz-Werner Scale, while it reached significance for the activities of daily living (Barthel Index) in favor of the GM1 -treated group (p <0.05).

KW - Cerebral ischemia

KW - Excitatory amino acids

KW - GM1 ganglioside therapy

KW - Monosialoganglioside

UR - http://www.scopus.com/inward/record.url?scp=20244389101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244389101&partnerID=8YFLogxK

U2 - 10.1159/000109009

DO - 10.1159/000109009

M3 - Article

AN - SCOPUS:20244389101

VL - 2

SP - 163

EP - 168

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 3

ER -